SEN. JOHNSON (D-S.D.) IS NEW DRUG PRICING CRITIC IN SENATE AFTER DEFEATING SEN. PRESSLER; ILLINOIS DEMOCRAT SEN. DURBIN IS STAUNCH ALLY OF FDA
Executive Summary
The pharmaceutical industry will have to contend with two new voices critical of its pricing practices in the Senate following the victories of Democrats Johnson (S.D.) and Durbin (Ill.) in Nov. 5 Senate races.